Nov 15, 2022 · We developed a very stable anti-CD79b-MMAE ADC (ARC-02) with this technology showing a higher therapeutic index (TI) compared to the approved ADC polatuzumab-vedotin (Polivy®) in different preclinical models.

Jul 15, 2007 · We show here that the stable-linker ADCs anti-CD79b-MCC-DM1 and anti-CD79b-MC-MMAF are capable of target-dependent killing of nonHodgkin lymphoma cell lines in vitro.

Sep 24, 2009 · Here we describe the generation of an antibody–drug conjugate (ADC) consisting of a humanized anti-CD79b antibody that is conjugated to monomethylauristatin E (MMAE) through engineered cysteines (THIOMABs) by a protease cleavable linker.

Apr 1, 2022 · We investigated DCDS0780A, an anti-CD79B ADC with THIOMAB technology (TDC) that consistently conjugates two anti-neoplastic molecules per antibody, in contrast with ADCs with heterogeneous loads.

Jul 15, 2007 · Targeting cytotoxic drugs to cancer cells using antibody-drug conjugates (ADCs), particularly those with stable linkers between the drug and the antibody, could be an effective cancer treatment with low toxicity.

Apr 1, 2022 · Targeting CD79B using antibody–drug conjugates (ADC) is an effective therapeutic strategy in B-cell non-Hodgkin lymphoma (B-NHL). We investigated DCDS0780A, an anti-CD79B ADC with THIOMAB technology (TDC) that consistently conjugates two anti-neoplastic molecules per antibody, in contrast with ADCs with heterogeneous loads.

Anti-CD79b antibody-drug conjugates (ADC), cytotoxic drugs linked through specialized chemical linkers to antibodies, are effective in mouse xenograft models of non-Hodgkin's lymphoma.

May 14, 2019 · In The Lancet Oncology, Hervé Tilly and colleagues 4 report a company-sponsored phase 1b–2 trial assessing the safety and activity of an ADC called polatuzumab vedotin—which targets CD79b to deliver monomethyl auristatin E, a small anti-tubulin agent—in combination with cyclophosphamide, doxorubicin, prednisone (CHP), and an anti-CD20 ...

For haematological cancers, immune lineage-specific biomarkers such as CD19, CD20, CD22, CD33, BCMA (B-cell maturation antigen), and CD79 are broadly and homogenously expressed on malignant haematological cells at high levels, and so have been extensively explored as candidate targets for ADC development . However, the same antigens are often ...

Jul 15, 2007 · We show here that the stable-linker ADCs anti-CD79b-MCC-DM1 and anti-CD79b-MC-MMAF are capable of target-dependent killing of nonHodgkin lymphoma cell lines in vitro.